Longevity-related claim: What’s allowed and not allowed?

Comment-period-opens-on-BAPP-draft-of-SOP-for-destruction-of-adulterated-ingredients.jpg
Industry experts have advised nutraceutical companies making longevity-related products to craft health claims based on authorized claims.

The healthy longevity supplement category has flourished in recent years, but making effective product health claims is still a key challenge due to a lag between regulatory and industry development, said an expert panel in last week’s Nutra Healthspan Summit held in London.

From raising NAD levels to supporting healthy mitochondrial function, products in the healthy longevity supplement category often feature ingredients such as nicotinamide mononucleotide (NMN) and make references to established scientific concepts such as the 12 hallmarks of aging.

However, having the science does not necessarily mean the companies are allowed to make corresponding claims.

For example, in Australia, nutraceutical companies selling NMN supplements are not allowed to make claims such as “raises NAD levels” in the body despite existing clinical evidence.

“You would think that that is a reasonably benign claim. It was supported by human clinical research showing if you take NMN, it raises NAD levels in the body. However, that was refused,” said Dr. Teresa Nicoletti, partner at Australia-based law firm Mills Oakley.

Dr. Nicoletti, also a PhD-qualified scientist with more than 30 years’ experience in Australia’s health and life sciences sector, raised the point during a panel discussion on the global longevity supplement sector and regulatory landscape.

On the panel were also Nataliia Polishchuk, global regulatory affairs manager, Nutrition & Health at Société des Produits Nestlé, Carlos Lopez, SVP and general counsel at Niagen Bioscience and Kristy Coleman, co-founder and solicitor at AK Collective. The discussion was moderated by Dr. Stephen Daniells, global editor-in-chief of NutraIngredients.

Explore related questions

Widely accepted and not accepted claims: What does the panel think?

Coleman similarly pointed out a gap between science and regulatory developments.

“We know that increasing NAD plus means increasing longevity. It’s not as simple as that,” she said. “Just because you’ve got the science to back it up doesn’t mean you can make the claim.”

In this case, she advised companies to consider alternative claims such as “support healthy aging” or “improves cellular energy”.

In fact, “supports healthy aging” is a claim which panellists believe will be widely accepted within five years, while claims like “extend lifespan” and “longevity” are unlikely to be allowed by regulators.

“In the United States at least, health claims around healthy aging are allowed if you have the proper evidence, although I do agree that validated endpoints would be hugely helpful, globally,” said Lopez. “Saying longevity itself might be problematic because it is impossible to do a clinical trial showing expansion of actual lifespan. That terminology might be problematic, but markers related to the hallmarks of aging and developing the appropriate biomarkers and building out your clinical science would allow claims like that going forward.”

Translate your claims

To navigate longevity-related health claims, Coleman added that companies would have to refer to authorized claims and translate their desired claims to fit into existing regulations.

“What you need to do is translate what you want to say and think about how you can marry that up with the authorized claims,” she said. “You just have to change the way in which you translate it and make it fit into the regulation rather than the other way around.”

In the UK and EU, for example, she pointed out that there are over 250 authorized claims related to cognition, physiology, psychology, immunity and bone health – which are all longevity-related claims that companies could consider.

Polishchuk concurred, adding that companies could consider underpinning healthy longevity with physiological function claims, including mental performance, muscle mass, hair and skin related claims.

To move the boundaries around longevity-related health claims, companies will ultimately have to start with building credible science, she said.

“If we want to talk about the future and what we want to establish regulatory-wise, we need to build science evidence, and we need to really defend it with the authorities that here is the evidence that we built,” she said.

Country differences

The panel also raised country-specific differences surrounding health claims such as supporting healthy mitochondrial function.

While the claim is permitted in the US, it is not the same case elsewhere in Australia, where the claim could be considered a structure-function claim. However, this is not the same as an indication or health claim that could be printed on the front-of-pack.

“A structure function claim is not an indication. A structure function claim is upstream from the indication. The TGA (Therapeutic Goods Administration) allows structure function claim as long as it is tied to a downstream effect,” said Dr. Nicoletti, adding that the industry has been working with the regulator to mitigate the differences.

In Indonesia, there are also instances where EFSA-authorized cognitive claim is not accepted by the local FDA.

“Certain authorities like Indonesia’s BPOM has rejected EFSA-authorized cognitive-related claim, as they believe that this is not only about nutrition and it goes beyond purely nutrition. It’s genetics. It’s multifactorial,” said Polishchuk.

“Authorities’ interpretation of science is different. Science could be said global, but claims and claims execution are local.”